查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1587794

淋巴瘤治療市場規模、佔有率、趨勢分析報告：2025-2030 年按類型、藥物、地區和細分市場預測

Lymphoma Treatment Market Size, Share & Trends Analysis Report By Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), By Drugs (Adcetris, Opdivo, Rituxan, Imbruvica, Keytruda), By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

淋巴瘤治療市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，預計2030年全球淋巴瘤治療市場規模將達119.7億美元，2025年至2030年複合年成長率為8.3%。

開發新治療方法和擴大產品陣容的研究活動的活性化可能會推動成長。新藥商業化的增加預計將進一步推動成長。

多種產品的出現預計將進一步促進成長。例如，2019年1月，百濟神州的治療成人套細胞淋巴瘤的產品Zanubrutinib獲得美國FDA突破性療法認定。該藥物目前正處於後期臨床試驗階段，預計將在預測期內上市。

醫療保健專業人員和患者對淋巴瘤早期診斷的認知不斷提高，以及政府對研發的資助不斷增加，預計將推動市場成長。例如，美國癌症研究所等研究機構獲得美國國會的資助，以支持與癌症相關的研究和相關活動。

淋巴瘤治療市場報告亮點

  • 非何傑金氏淋巴瘤(NHL) 佔據市場主導地位，到 2024 年，其銷售佔有率將達到 86.2%，預計在未來幾年，由於 NHL 盛行率不斷上升，病例數將大幅增加。
  • 由於診斷病例數量的增加以及促進早期檢測的診斷技術的進步，預計何傑金氏淋巴瘤(HL) 在預測期內將以 15.7% 的複合年成長率成長。
  • Rituxan（MabThera）佔據市場主導地位，2024 年佔據最大銷售佔有率，為 28.8%。這是由於其已確定的功效並廣泛用於多種適應症，尤其是非非何傑金氏淋巴瘤(NHL)。
  • Keytruda 預計在預測期內以 18.9% 的複合年成長率成長最快，因為它是一種領先的免疫療法選擇，特別是對於晚期或難治性病例。
  • 醫院藥局佔據市場主導地位，2024 年銷售佔有率最大，為 36.1%。
  • 北美淋巴瘤治療市場主導全球市場，2024年佔最大銷售量49.0%，這是由於淋巴瘤病例，尤其非何傑金氏淋巴瘤的高盛行率。
  • 由於發病率上升和醫療保健支出增加，亞太地區淋巴瘤治療市場預計將快速成長。該地區國家的醫療基礎設施正在改善，創新治療方法也不斷改善。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章淋巴瘤治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章 淋巴瘤治療市場：藥物評估與趨勢分析

  • 細分儀表板
  • 淋巴瘤治療市場：2024 年和 2030 年藥物變化分析
  • 何傑金氏淋巴瘤
  • 非何傑金氏淋巴瘤

第5章淋巴瘤治療市場：藥物評估與趨勢分析

  • 細分儀表板
  • 淋巴瘤治療市場：2024 年和 2030 年藥物變化分析
  • Rituxan/MabThera
  • Revlimid
  • 伊布魯維察
  • ADCETRIS
  • 密鑰楚達
  • Opdivo
  • 其他

第6章 淋巴瘤治療市場：通路估計與趨勢分析

  • 細分儀表板
  • 淋巴瘤治療市場：2024 年和 2030 年分銷管道變化分析
  • 醫院藥房
  • 零售藥房
  • 專業藥房
  • 其他

第7章淋巴瘤治療市場：區域估計與趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 南非
    • 阿拉伯聯合大公國

第8章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • Bristol-Myers Squibb Company
    • Celgene Corporation
    • Merck &Co., Inc.
    • F. Hoffmann-La Roche Ltd
    • Seattle Genetics, Inc.
    • Takeda Pharmaceutical Company Ltd
    • Johnson &Johnson
    • Eli Lilly and Company
    • AstraZeneca
    • Novartis AG
Product Code: GVR-3-68038-983-8

Lymphoma Treatment Market Growth & Trends:

The global lymphoma treatment market size is expected to reach USD 11.97 billion by 2030, registering a CAGR of 8.3% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising research activities for development of new treatments and increasing product line extension are likely to expedite growth. Increasing commercialization of novel drugs are further expected to drive the growth.

Availability of wide variety of products is further expected to aid growth. For instance, in January 2019, BeiGene received a breakthrough therapy designation by the U.S. FDA for its product Zanubrutinib for treating mantle cell lymphoma in adults. This drug is currently in late-stage clinical trial and is expected to be launched during the forecast period.

Growing awareness about early diagnosis of lymphoma among healthcare professionals & patients and rising government funding for R&D are some factors expected to propel market growth. For instance, institutes such as National Cancer Institute receives funding from the U.S. Congress to support cancer-related research and associated activities.

Lymphoma Treatment Market Report Highlights:

  • Non-Hodgkin Lymphoma (NHL) dominated the market with the largest revenue share of 86.2% in 2024, driven by the increasing incidence of NHL, with projections indicating a significant rise in cases over the coming years.
  • Hodgkin Lymphoma (HL) is expected to grow at a CAGR of 15.7% over the forecast period attributed to a rising number of diagnosed cases and advancements in diagnostic technologies that facilitate earlier detection.
  • Rituxan (MabThera) dominated the market and accounted for the largest revenue share of 28.8% in 2024, attributed to its established efficacy and broad usage across various indications, particularly non-Hodgkin lymphoma (NHL).
  • Keytruda is expected to grow at the fastest CAGR of 18.9% over the forecast period, owing to its status as a leading immunotherapy option, particularly for advanced or refractory cases.
  • Hospital pharmacies dominated the market and accounted for the largest revenue share of 36.1% in 2024 attributed to the increasing prevalence of lymphoma cases requiring specialized care.
  • The lymphoma treatment market in North America dominated the global market and accounted for the largest revenue share of 49.0% in 2024, owing to the high prevalence of lymphoma cases, particularly non-Hodgkin lymphoma, which accounts for a significant portion of cancer diagnoses.
  • The Asia Pacific lymphoma treatment market is projected to grow rapidly due to rising incidence rates and increasing healthcare spending. Countries in this region are experiencing improvements in healthcare infrastructure and access to innovative treatments

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Type
    • 1.2.2. Drug
    • 1.2.3. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Lymphoma Treatment Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrant
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Lymphoma Treatment Market: Drug Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 4.3. Hodgkin Lymphoma
    • 4.3.1. Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Non-Hodgkin Lymphoma
    • 4.4.1. Non-Hodgkin Lymphoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Lymphoma Treatment Market: Drug Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Lymphoma Treatment Market: Drug Movement Analysis, 2024 & 2030 (USD Million)
  • 5.3. Rituxan/MabThera
    • 5.3.1. Rituxan/MabThera Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Revlimid
    • 5.4.1. Revlimid Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Imbruvica
    • 5.5.1. Imbruvica Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Adcetris
    • 5.6.1. Adcetris Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Keytruda
    • 5.7.1. Keytruda Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Opdivo
    • 5.8.1. Opdivo Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Others
    • 5.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Lymphoma Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Lymphoma Treatment Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
  • 6.3. Hospital Pharmacy
    • 6.3.1. Hospital Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacy
    • 6.4.1. Retail Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Specialty Pharmacy
    • 6.5.1. Specialty Pharmacy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Lymphoma Treatment Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. UAE
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. UAE Lymphoma Treatment Market estimates and forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Bristol-Myers Squibb Company
      • 8.4.1.1. Overview
      • 8.4.1.2. Financial performance
      • 8.4.1.3. Product benchmarking
      • 8.4.1.4. Strategic initiatives
    • 8.4.2. Celgene Corporation
      • 8.4.2.1. Overview
      • 8.4.2.2. Financial performance
      • 8.4.2.3. Product benchmarking
      • 8.4.2.4. Strategic initiatives
    • 8.4.3. Merck & Co., Inc.
      • 8.4.3.1. Overview
      • 8.4.3.2. Financial performance
      • 8.4.3.3. Product benchmarking
      • 8.4.3.4. Strategic initiatives
    • 8.4.4. F. Hoffmann-La Roche Ltd
      • 8.4.4.1. Overview
      • 8.4.4.2. Financial performance
      • 8.4.4.3. Product benchmarking
      • 8.4.4.4. Strategic initiatives
    • 8.4.5. Seattle Genetics, Inc.
      • 8.4.5.1. Overview
      • 8.4.5.2. Financial performance
      • 8.4.5.3. Product benchmarking
      • 8.4.5.4. Strategic initiatives
    • 8.4.6. Takeda Pharmaceutical Company Ltd
      • 8.4.6.1. Overview
      • 8.4.6.2. Financial performance
      • 8.4.6.3. Product benchmarking
      • 8.4.6.4. Strategic initiatives
    • 8.4.7. Johnson & Johnson
      • 8.4.7.1. Overview
      • 8.4.7.2. Financial performance
      • 8.4.7.3. Product benchmarking
      • 8.4.7.4. Strategic initiatives
    • 8.4.8. Eli Lilly and Company
      • 8.4.8.1. Overview
      • 8.4.8.2. Financial performance
      • 8.4.8.3. Product benchmarking
      • 8.4.8.4. Strategic initiatives
    • 8.4.9. AstraZeneca
      • 8.4.9.1. Overview
      • 8.4.9.2. Financial performance
      • 8.4.9.3. Product benchmarking
      • 8.4.9.4. Strategic initiatives
    • 8.4.10. Novartis AG
      • 8.4.10.1. Overview
      • 8.4.10.2. Financial performance
      • 8.4.10.3. Product benchmarking
      • 8.4.10.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Global Lymphoma Treatment Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 5 Global Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 6 Global Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 7 North America Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 9 North America Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 10 North America Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 11 U.S Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 12 U.S Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 13 U.S Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 14 Canada Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 16 Canada Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 17 Mexico Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 19 Mexico Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 20 Europe Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Europe Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 23 Europe Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 24 UK Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 25 UK Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 26 UK Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 27 Germany Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 29 Germany Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 30 France Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 31 France Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 32 France Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 33 Italy Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 35 Italy Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 36 Spain Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 38 Spain Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 39 Asia Pacific Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 40 Asia Pacific Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 41 Asia Pacific Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 42 Asia Pacific Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 43 Japan Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 44 Japan Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 45 Japan Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 46 China Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 47 China Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 48 China Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 49 India Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 50 India Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 51 India Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 52 Australia Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 53 Australia Lymphoma Treatment Market, by portability, 2018 - 2030 (USD Million)
  • Table 54 Australia Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 55 Australia Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 57 South Korea Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 58 South Korea Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 59 Latin America Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 60 Latin America Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 61 Latin America Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 62 Latin America Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 63 Brazil Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 64 Brazil Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 65 Brazil Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 66 Argentina Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 67 Argentina Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 68 Argentina Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 69 Middle East & Africa Lymphoma Treatment Market, by Country, 2018 - 2030 (USD Million)
  • Table 70 Middle East & Africa Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 71 Middle East & Africa Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 72 Middle East & Africa Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 73 South Africa Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 74 South Africa Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 75 South Africa Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)
  • Table 76 UAE Lymphoma Treatment Market, by Type, 2018 - 2030 (USD Million)
  • Table 77 UAE Lymphoma Treatment Market, by Drug, 2018 - 2030 (USD Million)
  • Table 78 UAE Lymphoma Treatment Market, by Distribution Channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Lymphoma treatment market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and type outlook (USD Million)
  • Fig. 10 Type, drug, and distribution channel outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Lymphoma treatment market dynamics
  • Fig. 13 Lymphoma treatment market: Porter's five forces analysis
  • Fig. 14 Lymphoma treatment market: PESTLE analysis
  • Fig. 15 Lymphoma treatment market: Type segment dashboard
  • Fig. 16 Lymphoma treatment market: Type market share analysis, 2024 & 2030
  • Fig. 17 Hodgkin lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 18 Non-Hodgkin lymphoma market, 2018 - 2030 (USD Million)
  • Fig. 19 Lymphoma treatment market: Drug segment dashboard
  • Fig. 20 Lymphoma treatment market: Drug market share analysis, 2024 & 2030
  • Fig. 21 Adcetris market, 2018 - 2030 (USD Million)
  • Fig. 22 Opdivo market, 2018 - 2030 (USD Million)
  • Fig. 23 Rituxan/MabThera market, 2018 - 2030 (USD Million)
  • Fig. 24 Imbruvica market, 2018 - 2030 (USD Million)
  • Fig. 25 Keytruda market, 2018 - 2030 (USD Million)
  • Fig. 26 Revlimid market, 2018 - 2030 (USD Million)
  • Fig. 27 Others market, 2018 - 2030 (USD Million)
  • Fig. 28 Lymphoma treatment market: Distribution Channel segment dashboard
  • Fig. 29 Lymphoma treatment market: Distribution Channel market share analysis, 2024 & 2030
  • Fig. 30 Hospital pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 31 Retail pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 32 Specialty pharmacy market, 2018 - 2030 (USD Million)
  • Fig. 33 Lymphoma treatment market revenue, by region
  • Fig. 34 Regional marketplace: Key takeaways
  • Fig. 35 Regional marketplace: Key takeaways
  • Fig. 36 North America lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 37 U.S. country dynamics
  • Fig. 38 U.S. lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 39 Canada country dynamics
  • Fig. 40 Canada lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 41 Mexico country dynamics
  • Fig. 42 Mexico lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 43 Europe lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 44 UK country dynamics
  • Fig. 45 UK lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 46 Germany country dynamics
  • Fig. 47 Germany lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 48 France country dynamics
  • Fig. 49 France lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 50 Italy country dynamics
  • Fig. 51 Italy lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 52 Spain country dynamics
  • Fig. 53 Spain lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 54 Norway country dynamics
  • Fig. 55 Norway lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 56 Sweden country dynamics
  • Fig. 57 Sweden lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 60 Asia Pacific lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 61 Japan country dynamics
  • Fig. 62 Japan lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 63 China country dynamics
  • Fig. 64 China lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 65 India country dynamics
  • Fig. 66 India lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 67 Australia country dynamics
  • Fig. 68 Australia lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 69 South Korea country dynamics
  • Fig. 70 South Korea lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 71 Thailand country dynamics
  • Fig. 72 Thailand lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 73 Latin America lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 74 Brazil country dynamics
  • Fig. 75 Brazil lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 76 Argentina country dynamics
  • Fig. 77 Argentina lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 78 MEA lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 79 South Africa country dynamics
  • Fig. 80 South Africa lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 81 Saudi Arabia country dynamics
  • Fig. 82 Saudi Arabia lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 83 UAE country dynamics
  • Fig. 84 UAE lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 85 Kuwait Key country dynamics
  • Fig. 86 Kuwait lymphoma treatment market, 2018 - 2030 (USD Million)
  • Fig. 87 Company categorization
  • Fig. 88 Company market position analysis
  • Fig. 89 Strategic framework